Women's Cancer Research Laboratory Publications

Publications 1977 - Present

Bast RC Jr, Byrd JC, Croce C, Hawk ET, Khuri FR, Pollock RE, Tsimberidou AM, Willett CG, Wilman CL, Holland-FreiCancer Medicine, 10th Edition, John Wiley & Sons, Inc, 2023.

HOLLAND-FREI CANCER MEDICINE
The latest edition of the gold-standard in cancer science and clinical oncology references

2025�C�ʰ��Գ�

. Targeting SIK2 with GRN-300 Potentiates Paclitaxel Efficacy in Triple-Negative Breast Cancer. Cancers (Basel) 18(11), 2026. e-Pub 2026. PMID: 42279425.
. DIRAS3-derived cyclic peptides disrupt KRAS-RAF interaction and KRAS nanoclustering, suppressing KRAS-driven pancreatic and ovarian tumors. iScience 28(11):113686, 2025. e-Pub 2025. PMID: 41244592.
. Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers. Clin Proteomics 22(1):33, 2025. e-Pub 2025. PMID: 41053579.
. DIRAS3 Inhibits Ovarian Cancer Cell Growth by Blocking the Fibronectin-Mediated Integrin ��1/FAK/AKT Signaling Pathway. Cells 14(16), 2025. e-Pub 2025. PMID: 40862729.
. GlycoKnow Ovarian: a Glycoprotein-based, Serum Diagnostic to Distinguish Ovarian Cancers from Benign Pelvic Masses. medRxiv, 2025. e-Pub 2025. PMID: 40661292.
. CA-125 as a Biomarker in Renal Medullary Carcinoma. Clinical Cancer Research 31(6):1057-1068, 2025. e-Pub 2025. PMID: 39836407.

2023�C2024

. IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer. BMC medicine 22(1), 2024. e-Pub 2024. PMID: 38769543.
. A metabolite-based liquid biopsy for detection of ovarian cancer. Biomarker Research 12(1), 2024. e-Pub 2024. PMID: 39192316.
. Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing Autophagy. Mol Cancer Res 22(9):840-851, 2024. e-Pub 2024. PMID: 38780897.
. Normal Risk Ovarian Screening Study: 21-Year Update. J Clin Oncol 42(10):1102-1109, 2024. e-Pub 2024. PMID: 38194613.
. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resist Updat 74:101077, 2024. e-Pub 2024. PMID: 38518726.
. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas. Autophagy 20(3):675-691, 2024. e-Pub 2024. PMID: 38169324.
. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer. Br J Cancer 130(5):861-868, 2024. e-Pub 2024. PMID: 38195887.
. Membrane anchoring of the DIRAS3 N-terminal extension permits tumor suppressor function. iScience 26(11):108151, 2023. e-Pub 2023. PMID: 37915607.
. Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium. Oncogene 42(33):2473-2484, 2023. e-Pub 2023. PMID: 37402882.

2021�C2022

. A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses. Clin Cancer Res 28(21):4669-4676, 2022. e-Pub 2022. PMID: 36037307.
. Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics. JAMA Netw Open 5(10):e2236626, 2022. e-Pub 2022. PMID: 36239936.
. Structure-Based Design of Stapled Peptides That Bind GABARAP and Inhibit Autophagy. J Am Chem Soc 144(32):14687-14697, 2022. e-Pub 2022. PMID: 35917476.
. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. Mol Oncol 16(13):2558-2574, 2022. e-Pub 2022. PMID: 35278271.
. Development of a multi-protein classifier for the detection of early stage ovarian cancer. Cancers (Basel) 14(13), 2022. e-Pub 2022. PMID: 35804849.
. Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display. ACS Chem Biol 17(6):1543-1555, 2022. e-Pub 2022. PMID: 35611948.
. Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 13(1):3352, 2022. e-Pub 2022. PMID: 35688808.
. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. J Clin Invest 132(11), 2022. e-Pub 2022. PMID: 35642638.
. One-Pot, One-Step Synthesis of Drug-Loaded Magnetic Multimicelle Aggregates. Bioconjug Chem 33(5):969-981, 2022. e-Pub 2022. PMID: 35522527.
. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis 10(9):65, 2021. e-Pub 2021. PMID: 34588424.
. Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers (Basel) 13(14), 2021. e-Pub 2021. PMID: 34298618.
. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol 113:20-27, 2021. e-Pub 2021. PMID: 33887301.
. Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. JCI Insight 6(11):e147929, 2021. e-Pub 2021. PMID: 33945502.
. A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. Cancers (Basel) 13(4):1-22, 2021. e-Pub 2021. PMID: 33671595.
. Circulating Cancer Biomarkers. Cancers (Basel) 13(4):1-5, 2021. e-Pub 2021. PMID: 33671847.
. A novel salt inducible kinase 2 inhibitor, ARN-3261, sensitizes ovarian cancer cell lines and xenografts to carboplatin. Cancers (Basel) 13(3):1-15, 2021. e-Pub 2021. PMID: 33503955.
. Directed evolution of cyclic peptides for inhibition of autophagy. Chem Sci 12(10):3526-3543, 2021. e-Pub 2021. PMID: 34163626.
. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy 17(1):1-382, 2021. e-Pub 2021. PMID: 33634751.
. Next steps in the early detection of ovarian cancer. Commun Med (Lond) 1(1):36, 2021. e-Pub 2021. PMID: 34676377.
. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. Tumour Biol 43(1):355-365, 2021. e-Pub 2021. PMID: 34957977.

2019�C2020

. Targeting progesterone signaling prevents metastatic ovarian cancer. Proc Natl Acad Sci U S A 117(50):31993-32004, 2020. e-Pub 2020. PMID: 33262282.
. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 29(12):2504-2512, 2020. e-Pub 2020. PMID: 33051337.
. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. Cancer 126(15):3579-3592, 2020. e-Pub 2020. PMID: 32484926.
. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32708856.
. Analysis of RAS protein in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. Proc Natl Acad Sci U S A 117(22):12121-12130, 2020. e-Pub 2020. PMID: 32424096.
. In vivo modeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genet 16(6):e1008808, 2020. e-Pub 2020. PMID: 32497036.
. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. Int J Cancer 146(6):1553-1567, 2020. e-Pub 2020. PMID: 31503345.
. Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers (Basel) 12(2):485, 2020. e-Pub 2020. PMID: 32092936.
. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer 126(4):894-907, 2020. e-Pub 2020. PMID: 31714594.
. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Cancer 126(4):725-736, 2020. e-Pub 2020. PMID: 31714597.
. DIRAS3 (ARHI) blocks RAS/MAPK signaling by binding directly to Ras and disrupting Ras clusters. Cell Rep 29(11):3448-3459.e6, 2019. e-Pub 2019. PMID: 31825828.
. Reply to Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer" Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer. Cancers (Basel) 11(9), 2019. e-Pub 2019. PMID: 31540545.
. 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clin Cancer Res 25(18):5702-5716, 2019. e-Pub 2019. PMID: 31391192.
. Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. J Geriatr Oncol 10(5):pii: S1879-4068(18)30284-4, 2019. e-Pub 2019. PMID: 30795923.
. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results from TAILORx. J Clin Oncol 37(22):JCO1900945, 2019. e-Pub 2019. PMID: 31150316.
. Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference. Cancer 125(12):1963-1972, 2019. e-Pub 2019. PMID: 30835824.
. Complementary longitudinal serum biomarkers to CA125 for early detection of ovarian cancer. Cancer Prev Res (Phila) 12(6):391-400, 2019. e-Pub 2019. PMID: 30967390.
. Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression. Cancers (Basel) 11(5):pii: E603, 2019. e-Pub 2019. PMID: 31052266.
. Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. Cancers (Basel) 11(5):pii: E596, 2019. e-Pub 2019. PMID: 31035430.
. DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. Cancers (Basel) 11(4):pii: E557, 2019. e-Pub 2019. PMID: 31003488.
. The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. Cancer 125(8):1267-1280, 2019. e-Pub 2019. PMID: 30620384.
. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multi-Protein Classifier for Ovarian Cancer Detection. Cancer Prev Res (Phila) 12(3):171-184, 2019. e-Pub 2019. PMID: 30709840.

2017�C2018

. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-��. Invest New Drugs 36(6):1103-1109, 2018. e-Pub 2018. PMID: 30311036.
. Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24(20):5072-5084, 2018. e-Pub 2018. PMID: 30084832.
. Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT. Bioconjug Chem 29(9):3180-3195, 2018. e-Pub 2018. PMID: 30168713.
. Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer 124(14):3000-3007, 2018. e-Pub 2018. PMID: 29689595.
. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound Obstet Gynecol 51(3):293-303, 2018. e-Pub 2018. PMID: 28639753.
. Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9(1):476, 2018. e-Pub 2018. PMID: 29396402.
. RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy 14(4):637-53, 2018. e-Pub 2018. PMID: 29368982.
. In Vivo Optical Detection and Spectral Triangulation of Carbon Nanotubes. ACS Appl Mater Interfaces 9(48):41680-41690, 2017. e-Pub 2017. PMID: 29131572.
. Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clin Cancer Res 23(19):5912-5922, 2017. e-Pub 2017. PMID: 28637689.
. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol 35(24):2838-2847, 2017. e-Pub 2017. PMID: 28692382.
. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 17(6):577-591, 2017. e-Pub 2017. PMID: 28468520.
. A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel. Clin Cancer Res 23(8):1945-1954, 2017. e-Pub 2017. PMID: 27678456.
. Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells. Oncotarget 8(11):17960-17980, 2017. e-Pub 2017. PMID: 28152500.
. Transcriptional Regulation of Core Autophagy and Lysosomal Genes by the Androgen Receptor Promotes Prostate Cancer Progression. Autophagy 13(3):506-21, 2017. e-Pub 2017. PMID: 27977328.

2015�C2016

. Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis 5(12):e281, 2016. e-Pub 2016. PMID: 27991913.
. Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer 16(1):824, 2016. e-Pub 2016. PMID: 27784287.
. Validation of a novel biomarker panel for the detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 25(9):1333-40, 2016. e-Pub 2016. PMID: 27448593.
. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell 30(2):273-289, 2016. e-Pub 2016. PMID: 27478041.
. Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. EBioMedicine 10:137-49, 2016. e-Pub 2016. PMID: 27492892.
. Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo. Med Oncol 33(7):73, 2016. e-Pub 2016. PMID: 27277757.
. Validation of a biomarker panel and longitudinal biomarker performance for early detection of ovarian cancer. Int J Gynecol Cancer 26(6):1070-7, 2016. e-Pub 2016. PMID: 27206285.
. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1��/cyclin D1 pathway. Oncogene 35(19):2506-17, 2016. e-Pub 2016. PMID: 26364616.
. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(10):1134-50, 2016. e-Pub 2016. PMID: 26858339.
. Weight Loss Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which Negatively Regulates Adipogenesis and Activates Autophagy via Akt-mTOR Inhibition. EBioMedicine 6:149-61, 2016. e-Pub 2016. PMID: 27211557.
. Tumor necrosis factor-�� and interferon-�� stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NF��B. Oncotarget 7(12):14871-84, 2016. e-Pub 2016. PMID: 26918940.
. Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes Cancer 7(3-4):60-72, 2016. e-Pub 2016. PMID: 27382431.
. Allele-specific reprogramming of cancer metabolism by the long non-coding RNA, CCAT2. Mol Cell 61(4):520-34, 2016. e-Pub 2016. PMID: 26853146.
. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget 7(3):3018-32, 2016. e-Pub 2016. PMID: 26689988.
. Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo. Lab Invest 96(1):37-48, 2016. e-Pub 2016. PMID: 26568293.
. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer 26(1):43-51, 2016. e-Pub 2016. PMID: 26588231.
. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. e-Pub 2016. PMID: 26799652.
. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15(11):668-79, 2015. e-Pub 2015. PMID: 26493647.
. Systematic review of criteria to interpret CA125 increments during monitoring of patients with advanced epithelial ovarian cancer. J Oncol Med Pract 1(1):1000101 (1-11), 2015. e-Pub 2015.
. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women with Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 33(24):2695-704, 2015. e-Pub 2015. PMID: 26195705.
. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death Dis 6:e1836, 2015. e-Pub 2015. PMID: 26247722.
. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc 90(8):996-1000, 2015. e-Pub 2015. PMID: 26211600.
. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. Cancer 121(6):806-16, 2015. e-Pub 2015. PMID: 25355050.
. Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res 13(3):393-401, 2015. e-Pub 2015. PMID: 25304686.
. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prev Res (Phila) 8(1):37-48, 2015. e-Pub 2015. PMID: 25388014.
. CDK5 regulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT activation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis. PLoS One 10(7):e0131833, 2015. e-Pub 2015. PMID: 26146988.

2013�C2014

. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 20(22):5708-19, 2014. e-Pub 2014. PMID: 24833662.
. Variant prostate carcinoma and elevated serum CA-125. Can J Urol 21(5):7442-8, 2014. e-Pub 2014. PMID: 25347368.
. ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death Differ 21(8):1275-89, 2014. e-Pub 2014. PMID: 24769729.
. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy 10(6):1071-1092, 2014. e-Pub 2014. PMID: 24879154.
. Risk Perception, Worry, and Test Acceptance in Average-Risk Women Undergoing Ovarian Cancer Screening. Am J Obstet Gynecol 210(3):257.e1-6, 2014. e-Pub 2014. PMID: 24246524.
. Expression and epigenetic regulation of angiogenesis related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics 8(12):1330-46, 2013. e-Pub 2013. PMID: 24135786.
. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119(19):3454-61, 2013. e-Pub 2013. PMID: 23983047.
. Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway. Int J Oncol 43(4):1194-204, 2013. e-Pub 2013. PMID: 23921511.
. Low-Grade Serous Carcinoma: New Concepts and Emerging Therapies. Gynecol Oncol 130(3):660-6, 2013. e-Pub 2013. PMID: 23707670.
. CA125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer 23(5):815-822, 2013. e-Pub 2013. PMID: 23669443.
. Follicle-stimulating hormone enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. Endocr Relat Cancer 20(3):415-429, 2013. e-Pub 2013. PMID: 23580589.
. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park) 27(6):548-56, 2013. e-Pub 2013. PMID: 23909069.
. The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. Cell Adh Migr 7(2):232-6, 2013. e-Pub 2013. PMID: 23357870.
. Conquering Cancer in Our Lifetime: New Diagnostic and Therapeutic Trends. Clin Chem 59(1):1-3, 2013. e-Pub 2013. PMID: 23204223.
. Reflection on the Discovery of Carcinoembryonic Antigen, Prostate-Specific Antigen, and Cancer Antigens CA125 and CA19-9. Clin Chem 59(1):22-31, 2013. e-Pub 2013. PMID: 23204222.
. Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol 3:58, 2013. e-Pub 2013. PMID: 23519775.

2011�C2012

. Paclitaxel Inhibits Ovarian Tumor Growth by Inducing Epithelial Cancer Cells to Benign Fibroblast-like cells. Cancer Lett 326(2):176-82, 2012. e-Pub 2012. PMID: 22902993.
. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther 13(11):1034-41, 2012. e-Pub 2012. PMID: 22895067.
. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47-53, 2012. e-Pub 2012. PMID: 22487539.
. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 12(1):243, 2012. e-Pub 2012. PMID: 22695491.
. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118(10):2603-14, 2012. e-Pub 2012. PMID: 22370716.
. Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene 31(19):2450-60, 2012. e-Pub 2012. PMID: 22056875.
. Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Towards Ovarian Cancer Diagnostics at the Point-of-Care. Cancer Prev Res (Phila) 5(5):706-16, 2012. e-Pub 2012. PMID: 22490510.
. Differential diagnosis of a pelvic mass: Improved algorithms and novel biomarkers. Int J Gynecol Cancer 22(10 Suppl 1):S5-8, 2012. e-Pub 2012. PMID: 22543921.
. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol 206(4):351.e1-8, 2012. e-Pub 2012. PMID: 22284961.
. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. e-Pub 2012. PMID: 22966490.
. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 206(4):349.e1-7, 2012. e-Pub 2012. PMID: 22301440.
. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene 31(1):68-79, 2012. e-Pub 2012. PMID: 21643014.
. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer 118(1):91-100, 2012. e-Pub 2012. PMID: 21717433.
. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J Exp Ther Oncol 10(2):155-62, 2012. e-Pub 2012. PMID: 23350355.
. Modulation of microRNA-194 and Cell Migration by HER2-targeting Trastuzumab in Breast Cancer. PLoS One 7(7):e41170, 2012. e-Pub 2012. PMID: 22829924.
. FOXO3a dependent mechanism of E1A-Induced chemosensitization. Cancer Res 71(21):6878-87, 2011. e-Pub 2011. PMID: 21911455.
. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2M arrest and autophagy. Cancer 117(19):4424-38, 2011. e-Pub 2011. PMID: 21491416.
. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol 68(4):1033-44, 2011. e-Pub 2011. PMID: 21340606.
. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer 11(10):719-725, 2011. e-Pub 2011. PMID: 21941283.
. The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. J Natl Cancer Inst 103(18):1403-22, 2011. e-Pub 2011. PMID: 21813412.
. Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel. Cancer Res 71(17):5806-17, 2011. e-Pub 2011. PMID: 21775522.
. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 122(3):548-53, 2011. e-Pub 2011. PMID: 21708402.
. Src Family Kinases and paclitaxel sensitivity. Cancer Biol Ther 12(4):260-9, 2011. e-Pub 2011. PMID: 21646863.
. Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3. J Med Chem 54(10):3549-63, 2011. e-Pub 2011. PMID: 21486047.
. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117(8):1661-9, 2011. e-Pub 2011. PMID: 21472713.
. Reproducibility of SELDI spectra across time and laboratories. Cancer Inform 10:45-64, 2011. e-Pub 2011. PMID: 21552492.
. A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer. Cancer Prev Res (Phila) 4(3):375-383, 2011. e-Pub 2011. PMID: 21372037.
. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 4(3):365-74, 2011. e-Pub 2011. PMID: 21372036.
. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer 11(1):22, 2011. e-Pub 2011. PMID: 21244707.
Yu Y, Feng W, Lu Z, Bast RC. PEG3 (paternally expressed 3). Atlas Genet Cytogenet Oncol Haematol 15(5):422-4, 2011. e-Pub 2011.

2009�C2010

. Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Mol Cancer Ther 9(12):3186-99, 2010. e-Pub 2010. PMID: 20889728.
. A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose response studies. Biometrics 66(4):1275-83, 2010. e-Pub 2010. PMID: 20337630.
. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 116(21):4980-90, 2010. e-Pub 2010. PMID: 20629079.
. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 203(3):228.e1-6, 2010. e-Pub 2010. PMID: 20471625.
. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell 18(2):109-121, 2010. e-Pub 2010. PMID: 20708153.
. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer 10(1):378, 2010. e-Pub 2010. PMID: 20642860.
. Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. Mol Med Rep 3(4):581-7, 2010. e-Pub 2010. PMID: 21472283.
. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 16(13):3299-318, 2010. e-Pub 2010. PMID: 20501613.
. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 116(12):2850-3, 2010. e-Pub 2010. PMID: 20564390.
. Stanniocalcin 1 and Ovarian Tumorigenesis. J Natl Cancer Inst 102(11):812-27, 2010. e-Pub 2010. PMID: 20484106.
. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol 31(3):209-15, 2010. e-Pub 2010. PMID: 20393825.
. ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Biosci Rep 30(3):159-68, 2010. e-Pub 2010. PMID: 19435463.
. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 117(3):440-5, 2010. e-Pub 2010. PMID: 20334903.
. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 28(13):2159-66, 2010. e-Pub 2010. PMID: 20368574.
. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol 3(1):9, 2010. e-Pub 2010. PMID: 20222977.
. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron 3(1):137-47, 2010. e-Pub 2010. PMID: 21209780.
. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle 9(1):140-6, 2010. e-Pub 2010. PMID: 20016289.
Thigpen JT, Alberts D, Birrer M, Copeland L, Coleman RL, Markman M, Bast RC, Eisenhauer EL, Fleming G, Fracasso PM, Gershenson DM, Herzog T, Monk B, Ozols RF, Rustin G, Shrader M, Ranganathan A. Current Challenges and Future Directions in the Management of Ovarian Cancer: Proceedings of the First Global Workshop on Ovarian Cancer. Clinical Ovarian Cancer 3:81-97, 2010. e-Pub 2010.
Yu Y, Lu Z, Luo RZ, Bast RC. DIRAS3 (DIRAS family, GTP binding RAS-like 3). Atlas Genet Cytogenet Oncol Haematol 14(8):714-6, 2010. e-Pub 2010.
. Project zero delay: A process for accelerating the activation of cancer clinical trials. J Clin Oncol 27(26):4433-40, 2009. e-Pub 2009. PMID: 19652061.
. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer 115(17):3897-908, 2009. e-Pub 2009. PMID: 19517469.
. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther 8(8):2375-82, 2009. e-Pub 2009. PMID: 19671744.
. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112(1):40-46, 2009. e-Pub 2009. PMID: 18851871.
. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol 112(1):60-67, 2009. e-Pub 2009. PMID: 19007973.
. CA125/MUC16 is dispensable for mouse development and reproduction. PLoS One 4(3):e4675, 2009. e-Pub 2009. PMID: 19262696.

2007�C2008

. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7(23):3747-58, 2008. e-Pub 2008. PMID: 19029832.
. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation 76(10):1081-1092, 2008. e-Pub 2008. PMID: 18637025.
. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54(12):e11-79, 2008. e-Pub 2008. PMID: 19042984.
. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118(12):3917-29, 2008. e-Pub 2008. PMID: 19033662.
. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian and pancreatic cancers. Mol Carcinog 47(9):701-706, 2008. e-Pub 2008. PMID: 18176935.
. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 110(2):196-201, 2008. e-Pub 2008. PMID: 18495222.
. Early detection of ovarian cancer. Biomark Med 2(3):291-303, 2008. e-Pub 2008. PMID: 20477415.
. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112(7):1489-502, 2008. e-Pub 2008. PMID: 18286529.
. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian Cancer Action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol 108(3):652-657, 2008. e-Pub 2008. PMID: 18096210.
. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108(2):402-408, 2008. e-Pub 2008. PMID: 18061248.
. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 107(3):526-531, 2007. e-Pub 2007. PMID: 17920110.
. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287-312, 2007. e-Pub 2007. PMID: 17954709.
. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Mol Cancer Ther 6(11):2843-57, 2007. e-Pub 2007. PMID: 18025271.
. Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 107(2):173-6, 2007. e-Pub 2007. PMID: 17950384.
. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol 106(3):490-497, 2007. e-Pub 2007. PMID: 17532030.
. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 28(1):174-82, 2007. e-Pub 2007. PMID: 16829690.
. Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. Front Biosci 12:2260-8, 2007. e-Pub 2007. PMID: 17127462.
. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9(4):R57, 2007. e-Pub 2007. PMID: 17764565.

2005�C2006

. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107(11):2730-2740, 2006. e-Pub 2006. PMID: 17063503.
. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33):5313-5327, 2006. e-Pub 2006. PMID: 17060676.
. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25(52):6986-6996, 2006. e-Pub 2006. PMID: 16715132.
. Biomarkers and clinical trial design. Gynecol Oncol 103(2 Suppl 1):S3-5, 2006. e-Pub 2006. PMID: 17027069.
. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 103(44):16472-16477, 2006. e-Pub 2006. PMID: 17060621.
. 4-HPR modulates gene expression in ovarian cells. Int J Cancer 119(5):1005-1013, 2006. e-Pub 2006. PMID: 16570282.
. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and Histone H4 expression via the PI3K pathway. Cell Cycle 5(15):1654-1661, 2006. e-Pub 2006. PMID: 16861913.
. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res 12(8):2404-2413, 2006. e-Pub 2006. PMID: 16638845.
. 10th Biennial Helene Harris Memorial Trust Meeting. Cancer Res 66(6):2904-2906, 2006. e-Pub 2006. PMID: 16540635.
. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 66(5):2740-8, 2006. e-Pub 2006. PMID: 16510595.
. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23(31):7919-7926, 2005. e-Pub 2005. PMID: 16258091.
. Potential markers that complement expression of CA 125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-277, 2005. e-Pub 2005. PMID: 16061277.
. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene 24(40):6174-6184, 2005. e-Pub 2005. PMID: 15940260.
. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium and colon. Clin Cancer Res 11(17):6116-6126, 2005. e-Pub 2005. PMID: 16144910.
. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res 65(15):6701-6710, 2005. e-Pub 2005. PMID: 16061651.
. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. Gynecol Oncol 98(2):182-192, 2005. e-Pub 2005. PMID: 15907982.
. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11(6):2149-2155, 2005. e-Pub 2005. PMID: 15788660.
. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280(3):2092-2104, 2005. e-Pub 2005. PMID: 15504738.
. Subcellular localization of p27KIP1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 11(2 Pt 1):632-637, 2005. e-Pub 2005. PMID: 15701850.
. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4(1):87-95, 2005. e-Pub 2005. PMID: 15611642.

2003�C2004

. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 22(20):4059-4066, 2004. e-Pub 2004. PMID: 15381683.
. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 10(19):6559-6566, 2004. e-Pub 2004. PMID: 15475444.
. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer. Cancer Res 64(16):5882-5890, 2004. e-Pub 2004. PMID: 15313933.
. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33(12):1219-1224, 2004. e-Pub 2004. PMID: 15122311.
. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10(10):3291-3300, 2004. e-Pub 2004. PMID: 15161682.
. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279(10):9653-9661, 2004. e-Pub 2004. PMID: 14670967.
. A genetically defined model for human ovarian cancer. Cancer Res 64(5):1655-1663, 2004. e-Pub 2004. PMID: 14996724.
. Overexpression of MEKK3 confers resistance to apoptosis through activation of NF��B. J Biol Chem 279(9):7576-7583, 2004. e-Pub 2004. PMID: 14662759.
. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 279(6):4339-4345, 2004. e-Pub 2004. PMID: 14625284.
. Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest 22(2):248-256, 2004. e-Pub 2004. PMID: 15199607.
. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 9(10 Pt 1):3534-3545, 2003. e-Pub 2003. PMID: 14506139.
. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 9(10 Pt 1):3660-3666, 2003. e-Pub 2003. PMID: 14506155.
. Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer 39(13):1818-1827, 2003. e-Pub 2003. PMID: 12932658.
. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet 12(15):1791-1800, 2003. e-Pub 2003. PMID: 12874100.
. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 63(14):4174-4180, 2003. e-Pub 2003. PMID: 12874023.
. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90(1):44-50, 2003. e-Pub 2003. PMID: 12821340.
. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 9(7):2727-2733, 2003. e-Pub 2003. PMID: 12855653.
. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278(26):23441-23450, 2003. e-Pub 2003. PMID: 12700233.
. Status of tumor markers in ovarian cancer screening. J Clin Oncol 21(10 Suppl):200-205, 2003. e-Pub 2003. PMID: 12743135.
. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 22(19):2897-2909, 2003. e-Pub 2003. PMID: 12771940.
. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 21(10 Suppl):129s-132s, 2003. e-Pub 2003. PMID: 12743127.
. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res 9(2):845-852, 2003. e-Pub 2003. PMID: 12576458.
. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 22(4):484-497, 2003. e-Pub 2003. PMID: 12555062.
. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88(1):73-79, 2003. e-Pub 2003. PMID: 12504632.
. Specific keynote: Molecular Therapeutics in Ovarian Cancer. Gynecol Oncol 88(1 Pt 2):S88-S92, 2003. e-Pub 2003. PMID: 12586094.

2001�C2002

. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 62(24):7264-7272, 2002. e-Pub 2002. PMID: 12499268.
. Heregulin-induced apoptosis. Apoptosis 7(6):483-491, 2002. e-Pub 2002. PMID: 12370490.
. Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. J Biomed Opt 7(1):20-26, 2002. e-Pub 2002. PMID: 11818008.
Kramer S, Yu Y, Jager W, Lang N, Bast RC, Beckmann MW. Characterization of the ARHI tumor suppressor as a target for gene therapy in ovarian cancer. Geburtsh Frauenheilk 62:870-876, 2002. e-Pub 2002.
. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C �� activity. Oncogene 20(57):8258-8269, 2001. e-Pub 2001. PMID: 11781840.
. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92(11):2837-2844, 2001. e-Pub 2001. PMID: 11753957.
. Translational research - traffic on the bridge. Biomed Pharmacother 55(9-10):565-571, 2001. e-Pub 2001. PMID: 11769968.
. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82(3):420-426, 2001. e-Pub 2001. PMID: 11520135.
. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 61(15):5895-5904, 2001. e-Pub 2001. PMID: 11479231.
. Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 10(8):889-893, 2001. e-Pub 2001. PMID: 11489756.
. Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. Biochim Biophys Acta 1519(3):216-222, 2001. e-Pub 2001. PMID: 11418188.
. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19(6):1865-1878, 2001. e-Pub 2001. PMID: 11251019.
. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol 19(6):1716-22, 2001. e-Pub 2001. PMID: 11251001.
. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-��. Gynecol Oncol 80(2):245-253, 2001. e-Pub 2001. PMID: 11161867.
. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol Oncol 80(2):145-155, 2001. e-Pub 2001. PMID: 11161852.
. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest 19(5):459-466, 2001. e-Pub 2001. PMID: 11458813.
. Fluorescence spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 29(2):128-135, 2001. e-Pub 2001. PMID: 11553899.
. Reflectance spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 28(1):56-66, 2001. e-Pub 2001. PMID: 11430444.

1999�C2000

. Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene 19(54):6277-6285, 2000. e-Pub 2000. PMID: 11175342.
. Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J 352 Pt 2:475-482, 2000. e-Pub 2000. PMID: 11085941.
. Long-term follow-up of the Stockholm screening study on ovarian cancer. Gynecol Oncol 79(3):466-470, 2000. e-Pub 2000. PMID: 11104621.
. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer 89(6):519-523, 2000. e-Pub 2000. PMID: 11102897.
. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J 352 Pt 1:135-143, 2000. e-Pub 2000. PMID: 11062066.
. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97(22):11960-11965, 2000. e-Pub 2000. PMID: 11035810.
. The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice. Cancer Res 60(17):4913-4920, 2000. e-Pub 2000. PMID: 10987306.
. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res 6(8):3334-3341, 2000. e-Pub 2000. PMID: 10955821.
. Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res 60(13):3522-3531, 2000. e-Pub 2000. PMID: 10910064.
. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. Int J Cancer 86(5):690-694, 2000. e-Pub 2000. PMID: 10797292.
. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25(11):1137-40, 2000. e-Pub 2000. PMID: 10849525.
. Molecular approaches to management of epithelial ovarian cancer. Int J Gynecol Cancer 10(S1):2-7, 2000. e-Pub 2000. PMID: 11240724.
. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 6(1):260-270, 2000. e-Pub 2000. PMID: 10656457.
. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res 5(12):4053-4058, 1999. e-Pub 1999. PMID: 10632339.
. Overexpression of Edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 5(12):4308-4318, 1999. e-Pub 1999. PMID: 10632375.
. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 18(48):6635-6640, 1999. e-Pub 1999. PMID: 10597268.
. Ovarian cancer identified through screening with serum markers but not by pelvic imaging. Int J Gynecol Cancer 9(6):497-501, 1999. e-Pub 1999. PMID: 11240818.
. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 5(11):3704-3710, 1999. e-Pub 1999. PMID: 10589790.
. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol 75(2):261-266, 1999. e-Pub 1999. PMID: 10525383.
. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5(11):3653-3660, 1999. e-Pub 1999. PMID: 10589783.
. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 86(7):1251-1257, 1999. e-Pub 1999. PMID: 10506711.
. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Nucl Med Biol 26(7):781-790, 1999. e-Pub 1999. PMID: 10628557.
. Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer 86(5):887-897, 1999. e-Pub 1999. PMID: 10463990.
. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 82(4):525-531, 1999. e-Pub 1999. PMID: 10404066.
. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 5(8):2164-2170, 1999. e-Pub 1999. PMID: 10473101.
. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. Clin Chem 45(5):692-694, 1999. e-Pub 1999. PMID: 10222361.
. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 73(1):56-61, 1999. e-Pub 1999. PMID: 10094881.
. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res 5(3):655-664, 1999. e-Pub 1999. PMID: 10100719.
. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 96(1):214-219, 1999. e-Pub 1999. PMID: 9874798.

1997�C1998

. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res 4(11):2717-2721, 1998. e-Pub 1998. PMID: 9829734.
. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin Cancer Res 4(10):2545-2550, 1998. e-Pub 1998. PMID: 9796989.
. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 70(3):404-409, 1998. e-Pub 1998. PMID: 9790795.
. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma 17(4):313-321, 1998. e-Pub 1998. PMID: 9790065.
. OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders. Int J Biol Markers 13(3):145-149, 1998. e-Pub 1998. PMID: 10079388.
. Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. Gynecol Oncol 70(1):49-55, 1998. e-Pub 1998. PMID: 9698473.
. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 58(10):2253-2259, 1998. e-Pub 1998. PMID: 9605774.
. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol 16(2):793-5, 1998. e-Pub 1998. PMID: 9469371.
. Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 16(1):1-8, 1998. e-Pub 1998. PMID: 9467937.
. Summary of the first Emil J Freireich symposium. Clin Cancer Res 3(12 Pt 2):2708-2710, 1997. e-Pub 1997. PMID: 10068278.
. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 15(21):2589-2596, 1997. e-Pub 1997. PMID: 9399646.
. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 3(9):1629-1634, 1997. e-Pub 1997. PMID: 9815853.
. Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl Med Biol 24(5):451-459, 1997. e-Pub 1997. PMID: 9290082.
. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant 3(2):91-97, 1997. e-Pub 1997. PMID: 9267669.
. Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J Biol Chem 272(21):13683-13689, 1997. e-Pub 1997. PMID: 9153219.
. Is OVX1 a suitable marker for endometrial cancer?. Gynecol Oncol 65(2):291-296, 1997. e-Pub 1997. PMID: 9159340.
. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ 12(3):166-173, 1997. e-Pub 1997. PMID: 9376255.
Woolas RP, Jacobs IJ, Xu F, Berchuck A, Soper JT, Clarke-Pearson DL, Spence-Jones C, Oram DH, Hudson CN, Shepherd JH, Bast RC. Multiple tumor marker measurements to differentiate stage I ovarian cancer from the benign ovarian cyst. J Gynecol Techniques 3:123-126, 1997. e-Pub 1997.
Sharp F, Blackett AD, Berek JS, Bast RC. Conclusions and recommendations of the Helene Harris Memorial Trust Sixth Biennial International Forum on Ovarian Cancer. Int J Gynec Oncol, Los Angeles, California, USA 7:416-424, 1997. e-Pub 1997.
Bast RC, Knapp RC. CA 125: History, current status, and future prospects. McGill J Med 3:67-71, 1997. e-Pub 1997.

1995�C1996

. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A 93(26):15346-51, 1996. e-Pub 1996. PMID: 8986814.
. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27(11):1185-1191, 1996. e-Pub 1996. PMID: 8912829.
. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88(20):1456-1466, 1996. e-Pub 1996. PMID: 8841020.
. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14(10):2843-77, 1996. e-Pub 1996. PMID: 8874347.
. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 62(1):89-99, 1996. e-Pub 1996. PMID: 8690299.
. Expression of cell regulatory proteins in ovarian borderline tumors. Cancer 77(10):2092-2098, 1996. e-Pub 1996. PMID: 8640675.
. Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. Gynecol Oncol 61(2):233-240, 1996. e-Pub 1996. PMID: 8626139.
. Expression of ��6 and ��4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol 148(5):1445-1461, 1996. e-Pub 1996. PMID: 8623916.
. Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. Am J Obstet Gynecol 174(4):1316-1319, 1996. e-Pub 1996. PMID: 8623863.
. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother 5(1):57-62, 1996. e-Pub 1996. PMID: 8646482.
. Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Clin Cancer Res 2(1):81-86, 1996. e-Pub 1996. PMID: 9816094.
Fayed S, Wu S, Lidor Y, Super M, Berchuck A, Bast RC, Wiener JR. Detection and partial purification of a 30 kDa ovarian carcinoma-associated protein. Cancer Mol Biol 3:915-926, 1996. e-Pub 1996.
. Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumour Biol 17(6):325-331, 1996. e-Pub 1996. PMID: 8938947.
. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat 41(1):1-13, 1996. e-Pub 1996. PMID: 8932871.
. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 17(4):196-219, 1996. e-Pub 1996. PMID: 8685601.
Woolas R, Xu FJ, Jacobs I, Oram D, Bast RC. Case Report: Elevated serum levels of macrophage colony stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer. Int J Gynecol Cancer 6:156-158, 1996. e-Pub 1996.
. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy. Bone Marrow Transplant 16(6):815-821, 1995. e-Pub 1995. PMID: 8750275.
. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76(10 Suppl):2004-2010, 1995. e-Pub 1995. PMID: 8634992.
. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 76(9):1615-1620, 1995. e-Pub 1995. PMID: 8635066.
. Spectral differences between epitopes in the cronomes of salivary CA130 and CA125. In Vivo 9(4):341-346, 1995. e-Pub 1995. PMID: 8555433.
. Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130. In Vivo 9(4):407-12, 1995. e-Pub 1995. PMID: 8555442.
. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor ��. Cancer Res 55(4):944-948, 1995. e-Pub 1995. PMID: 7531618.
. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59:111-116, 1995. e-Pub 1995. PMID: 7557595.

1993�C1994

. Transforming growth factor �� 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 5(12):1301-1307, 1994. e-Pub 1994. PMID: 7696178.
. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. Int J Cancer 59(2):242-247, 1994. e-Pub 1994. PMID: 7927925.
. Regulation of tumour necrosis factor-�� processing by a metalloproteinase inhibitor. Nature 370(6490):558-561, 1994. e-Pub 1994. PMID: 8052311.
. Transforming growth factor-? inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74(1):93-99, 1994. e-Pub 1994. PMID: 8004589.
. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 83(11):3132-3137, 1994. e-Pub 1994. PMID: 8193351.
. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73(9):2380-2385, 1994. e-Pub 1994. PMID: 7909491.
. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 170(5 Pt 1):1285-1296, 1994. e-Pub 1994. PMID: 8178854.
. Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-��) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-��. Gynecol Oncol 53(1):59-63, 1994. e-Pub 1994. PMID: 8175024.
. OVX1 as a marker for early stage endometrial carcinoma. Cancer 73(7):1855-1858, 1994. e-Pub 1994. PMID: 8137210.
. Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. Am J Obstet Gynecol 170(4):1177-1183, 1994. e-Pub 1994. PMID: 8166206.
. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum Mol Genet 3(4):589-594, 1994. e-Pub 1994. PMID: 8069304.
. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst 86(5):372-378, 1994. e-Pub 1994. PMID: 7905928.
. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 56(4):552-559, 1994. e-Pub 1994. PMID: 8112891.
. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 52(2):232-236, 1994. e-Pub 1994. PMID: 7508877.
. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 101(2):192-197, 1994. e-Pub 1994. PMID: 8116574.
. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170(1 Pt 1):246-252, 1994. e-Pub 1994. PMID: 8296829.
. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 83(1):118-124, 1994. e-Pub 1994. PMID: 8272291.
. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 30A(8):1096-1099, 1994. e-Pub 1994. PMID: 7654437.
Abou-Ghalia A, Silva O, Vredenburgh JJ, Bast RC. Advances in the detection of marrow micrometastases in breast cancer. Cancer Res Ther Control 4:43-47, 1994. e-Pub 1994.
Kassim SK, Wiener JR, Berchuck A, Bast RC. Protein tyrosine phosphatases: Biology and role in human cancers. Cancer Mol Biol 1:133-144, 1994. e-Pub 1994.
. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol 100(12):1120-1124, 1993. e-Pub 1993. PMID: 8297846.
. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85(21):1748-1751, 1993. e-Pub 1993. PMID: 8411259.
. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J Clin Invest 92(5):2440-2447, 1993. e-Pub 1993. PMID: 8227359.
. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85(18):1513-1519, 1993. e-Pub 1993. PMID: 8360934.
. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. Am J Obstet Gynecol 169(3):690-694, 1993. e-Pub 1993. PMID: 8372881.
. National Cancer Institute Conference on Investigational Strategies for Detection and Intervention in Early Ovarian Cancer. Cancer Res 53(16):3839-3842, 1993. e-Pub 1993. PMID: 8339296.
. Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res 207(2):332-339, 1993. e-Pub 1993. PMID: 8344385.
. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J Clin Oncol 11(8):1506-1510, 1993. e-Pub 1993. PMID: 8336189.
. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 71(12):3942-3946, 1993. e-Pub 1993. PMID: 8099528.
. Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 99(6):736-740, 1993. e-Pub 1993. PMID: 8322710.
. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11(6):1132-1143, 1993. e-Pub 1993. PMID: 8501500.
. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81(5 Pt 1):643-650, 1993. e-Pub 1993. PMID: 8469448.
. Tumor necrosis factor alpha (TNF-��) as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and TNF-�� expression. Cancer Res 53(8):1939-1944, 1993. e-Pub 1993. PMID: 8385577.
. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 53(6):1218-1221, 1993. e-Pub 1993. PMID: 8095178.
. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 53(3):401-408, 1993. e-Pub 1993. PMID: 7679090.
. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am J Obstet Gynecol 168(1 Pt 1):228-232, 1993. e-Pub 1993. PMID: 8420332.
Woolas R, Xu FJ, Daly L, Soper JT, Berchuck A, Rodriguez G, Clarke-Pearson DL, Boyer CM, Bast RC. Screening strategies for ovarian cancer. Diagn Oncol 3:287-293, 1993. e-Pub 1993.

1991�C1992

. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 84(23):1793-1798, 1992. e-Pub 1992. PMID: 1433368.
. The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. Am J Obstet Gynecol 167(6):1877-1882, 1992. e-Pub 1992. PMID: 1361720.
. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer 70(8):2137-2142, 1992. e-Pub 1992. PMID: 1394043.
. Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma. Cancer 70(5):1115-1123, 1992. e-Pub 1992. PMID: 1515986.
. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 80(3 Pt 1):396-399, 1992. e-Pub 1992. PMID: 1495694.
. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80(1):14-18, 1992. e-Pub 1992. PMID: 1603484.
. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. J Clin Oncol 10(7):1057-1065, 1992. e-Pub 1992. PMID: 1607912.
. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy. Chronobiologia 19(3-4):131-49, 1992. e-Pub 1992. PMID: 1362146.
. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 40(7):1047-1051, 1992. e-Pub 1992. PMID: 1607637.
. Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. Cancer 69(12):2894-2904, 1992. e-Pub 1992. PMID: 1375528.
. Ha-ras polymorphisms in epithelial ovarian cancer. Gynecol Oncol 45(3):229-302, 1992. e-Pub 1992. PMID: 1351862.
. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52(6):1622-1627, 1992. e-Pub 1992. PMID: 1540970.
. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-��. Am J Obstet Gynecol 166(3):997-1007, 1992. e-Pub 1992. PMID: 1550178.
. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-?. Am J Obstet Gynecol 166(2):676-684, 1992. e-Pub 1992. PMID: 1536252.
. Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecol Oncol 44(1):61-65, 1992. e-Pub 1992. PMID: 1370427.
. Detection of minimal residual breast cancer in bone marrow. Prog Clin Biol Res 377:637-642, 1992. e-Pub 1992. PMID: 1438446.
. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 49(5):704-710, 1991. e-Pub 1991. PMID: 1937956.
. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 165(5 Pt 1):1356-1362, 1991. e-Pub 1991. PMID: 1957862.
. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 68(8):1758-1763, 1991. e-Pub 1991. PMID: 1913520.
. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res 51(19):5361-5369, 1991. e-Pub 1991. PMID: 1680547.
. Insurance coverage of screening mammography and Pap smears. The directors of North Carolina's University-based cancer centers speak out. N C Med J 52(10):496-498, 1991. e-Pub 1991. PMID: 1944619.
. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer 68(6):1272-1278, 1991. e-Pub 1991. PMID: 1873781.
. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol 165(3):640-646, 1991. e-Pub 1991. PMID: 1679963.
. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51(11):2908-2916, 1991. e-Pub 1991. PMID: 1709586.
. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51(11):2979-2984, 1991. e-Pub 1991. PMID: 2032235.
. Summary of symposium: Biology and therapy of ovarian cancer. Semin Oncol 18(3):297-306, 1991. e-Pub 1991. PMID: 2042066.
. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 164(3):745-750, 1991. e-Pub 1991. PMID: 2003535.
. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 7(2):145-151, 1991. e-Pub 1991. PMID: 2049558.
. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164(2):669-674, 1991. e-Pub 1991. PMID: 1992720.
. Coexpression of different antigenic markers on moieties that bear CA 125 determinants. Cancer Res 51(2):468-475, 1991. e-Pub 1991. PMID: 1702359.
. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164(1 Pt 1):15-21, 1991. e-Pub 1991. PMID: 1670908.
. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 9(1):85-93, 1991. e-Pub 1991. PMID: 1985173.

1989�C1990

. Reactivity of polyclonal and two monoclonal antibodies with cell subsets isolated from cystic fluids of ovarian serous neoplasms. Tumori 76(5):505-510, 1990. e-Pub 1990. PMID: 1701581.
. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 163(4 Pt 1):1164-1167, 1990. e-Pub 1990. PMID: 2171337.
. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol 163(4 Pt 1):1204-1209, 1990. e-Pub 1990. PMID: 2220931.
. CA 125 levels in menopausal women. Obstet Gynecol 76(3 Pt 1):428-431, 1990. e-Pub 1990. PMID: 2381621.
. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 38(3):386-391, 1990. e-Pub 1990. PMID: 2121627.
. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol 76(3 Pt 1):381-387, 1990. e-Pub 1990. PMID: 1974342.
. The Duke AFM program. Intensive induction chemotherapy for metastatic breast cancer. Cancer 66(3):431-436, 1990. e-Pub 1990. PMID: 2364358.
. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol 94(1):8-13, 1990. e-Pub 1990. PMID: 2193508.
. Antigenic heterogeneity in human ovarian cancer. Gynecol Oncol 38(1):12-16, 1990. e-Pub 1990. PMID: 2162315.
. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50(13):4087-4091, 1990. e-Pub 1990. PMID: 1972347.
. Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. Cancer Res 50(11):3231-3238, 1990. e-Pub 1990. PMID: 2334918.
. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'- deoxycoformycin, deoxyadenosine and an immunotoxin. Bone Marrow Transplant 5(6):395-402, 1990. e-Pub 1990. PMID: 2369680.
. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol 162(4):883-888, 1990. e-Pub 1990. PMID: 2327461.
. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 36(3):299-305, 1990. e-Pub 1990. PMID: 2318438.
. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol 36(2):161-165, 1990. e-Pub 1990. PMID: 2404835.
. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol 75(2):249-254, 1990. e-Pub 1990. PMID: 2300353.
. The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol 75(2):255-262, 1990. e-Pub 1990. PMID: 2300354.
. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. Prog Clin Biol Res 333:321-335; discussion 336, 1990. e-Pub 1990. PMID: 2308989.
. Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. Am J Obstet Gynecol 161(5):1258-1263, 1989. e-Pub 1989. PMID: 2589448.
. Epidermal growth factor receptor expression in normal and malignant endometrium. Am J Obstet Gynecol 161(5):1247-1252, 1989. e-Pub 1989. PMID: 2480065.
. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol 7(11):1594-1601, 1989. e-Pub 1989. PMID: 2809677.
. Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues. Arch Pathol Lab Med 113(10):1155-1158, 1989. e-Pub 1989. PMID: 2802945.
. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 49(16):4659-4664, 1989. e-Pub 1989. PMID: 2663144.
. Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. Cancer Res 49(11):2928-2934, 1989. e-Pub 1989. PMID: 2497969.
. Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Cancer Res 49(8):2091-2095, 1989. e-Pub 1989. PMID: 2702650.
. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest 83(3):921-926, 1989. e-Pub 1989. PMID: 2646321.
. CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. Am J Obstet Gynecol 160(2):354-355, 1989. e-Pub 1989. PMID: 2644834.
. Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. Int J Cancer 43(1):55-60, 1989. e-Pub 1989. PMID: 2463226.
. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol 23(6):377-383, 1989. e-Pub 1989. PMID: 2653660.
. Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. Int J Rad Appl Instrum B 16(4):405-411, 1989. e-Pub 1989. PMID: 2777582.
. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. Acta Oncol 28(5):655-657, 1989. e-Pub 1989. PMID: 2590540.

1987�C1988

. Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. Cancer Res 48(19):5604-5609, 1988. e-Pub 1988. PMID: 3046744.
. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6(9):1368-1376, 1988. e-Pub 1988. PMID: 3047332.
. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 159(2):341-346, 1988. e-Pub 1988. PMID: 2457318.
. Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. Transplantation 46(1):57-60, 1988. e-Pub 1988. PMID: 3293287.
. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 30(1):7-14, 1988. e-Pub 1988. PMID: 2452773.
. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318(14):869-876, 1988. e-Pub 1988. PMID: 3281007.
. Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination. Int J Biol Markers 3(2):75-81, 1988. e-Pub 1988. PMID: 3243980.
. Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. Int J Rad Appl Instrum B 15(4):431-437, 1988. e-Pub 1988. PMID: 3255739.
Kenemans P, Bast RC, Yedema CA, Price MR, Hilgers J. CA 125 and polymorphic epithelial mucin as serum tumor markers. Cancer Rev 11-12:119-144, 1988. e-Pub 1988.
Endo K, Matsuoka Y, Nakashima T, Fujii S, Kunimatsu M, Saga T, Watanabe Y, Kawamura Y, Koizumi M, Konishi J, Torizuka K, Bast RC. Development of a new sensitive immunoradiometric assay for CA125: Mixed use of two monoclonal antibodies reactive with separate epitopes. J Tumor Marker Oncol 3:65-71, 1988. e-Pub 1988.
. The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. Biochem Biophys Res Commun 149(3):969-974, 1987. e-Pub 1987. PMID: 3426621.
. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47(23):6402-6406, 1987. e-Pub 1987. PMID: 2824032.
. Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer. Int J Cancer 40(5):592-597, 1987. e-Pub 1987. PMID: 2445699.
. Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement. Cancer Res 47(17):4608-4612, 1987. e-Pub 1987. PMID: 3113721.
. The effect of LPS on expression of the early "competence" genes JE and KC in murine peritoneal macrophages. J Immunol 138(11):3891-3896, 1987. e-Pub 1987. PMID: 3108379.
. Homologous and heterologous desensitization of proto-oncogene cfos expression in murine peritoneal macrophages. J Cell Physiol 131(1):36-42, 1987. e-Pub 1987. PMID: 3571335.
. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol 69(4):606-611, 1987. e-Pub 1987. PMID: 2434895.
. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69(2):223-227, 1987. e-Pub 1987. PMID: 2433652.
. Co-expression of human cancer-associated epitopes on mucin molecules. Int J Cancer 39(1):68-72, 1987. e-Pub 1987. PMID: 2432019.
. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep 71:119-125, 1987. e-Pub 1987. PMID: 3542208.

1985�C1986

. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 46(12 Pt 1):6143-6148, 1986. e-Pub 1986. PMID: 2430690.
. Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. J Immunol 137(8):2711-2715, 1986. e-Pub 1986. PMID: 3760571.
. Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. Cancer Res 46(9):4496-4499, 1986. e-Pub 1986. PMID: 3524814.
. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 155(1):56-60, 1986. e-Pub 1986. PMID: 3460341.
. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 67(5):685-689, 1986. e-Pub 1986. PMID: 3457330.
. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril 45(5):630-634, 1986. e-Pub 1986. PMID: 3457709.
. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. J Clin Oncol 4(5):646-654, 1986. e-Pub 1986. PMID: 3517240.
. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody: Ricin A chain conjugates. Cancer Res 46(3):1208-1213, 1986. e-Pub 1986. PMID: 3510720.
. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 67(3):414-416, 1986. e-Pub 1986. PMID: 2418395.
. Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. Leuk Res 10(1):35-42, 1986. e-Pub 1986. PMID: 2935682.
. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol 3(10):1355-1363, 1985. e-Pub 1985. PMID: 2413181.
. Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. Ann Surg 202(4):440-445, 1985. e-Pub 1985. PMID: 4051597.
. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol 22(1):115-20, 1985. e-Pub 1985. PMID: 2410329.
. A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients. Am J Obstet Gynecol 152(7 Pt 1):911-913, 1985. e-Pub 1985. PMID: 2411137.
. Recombinant leukocyte �� interferon in advanced ovarian carcinoma. Cancer Treat Rep 69(7-8):895-896, 1985. e-Pub 1985. PMID: 4016797.
. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 19(6):354-356, 1985. e-Pub 1985. PMID: 4018373.
. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood 65(5):1064-1070, 1985. e-Pub 1985. PMID: 3995166.
. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 151(7):981-986, 1985. e-Pub 1985. PMID: 3157319.
. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture. Cancer Res 45(2):758-767, 1985. e-Pub 1985. PMID: 3967246.
. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 45(2):499-503, 1985. e-Pub 1985. PMID: 3967224.
. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obstet Gynecol 152:1003-1010, 1985. e-Pub 1985. PMID: 2992276.
. Chemotactic anti-tumor antibodies - in vitro results with four different antibody preparations. Adv Exp Med Biol 186:827-832, 1985. e-Pub 1985. PMID: 4050600.

1983�C1984

. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 64(5):703-707, 1984. e-Pub 1984. PMID: 6208522.
. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol 64(5):708-714, 1984. e-Pub 1984. PMID: 6493663.
. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet 2(8400):427-431, 1984. e-Pub 1984. PMID: 6147502.
. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum. J Biol Response Mod 3(4):371-378, 1984. e-Pub 1984. PMID: 6541243.
. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol 149(5):553-559, 1984. e-Pub 1984. PMID: 6204531.
. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res 44(7):2813-2819, 1984. e-Pub 1984. PMID: 6202400.
. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148(8):1057-1058, 1984. e-Pub 1984. PMID: 6201072.
. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 44(3):1048-1053, 1984. e-Pub 1984. PMID: 6198078.
. Somatic activation of rasK gene in a human ovarian carcinoma. Science 223(4637):698-701, 1984. e-Pub 1984. PMID: 6695178.
. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer 32(5):547-554, 1983. e-Pub 1983. PMID: 6358053.
. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309(15):883-887, 1983. e-Pub 1983. PMID: 6310399.
. Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. Am J Obstet Gynecol 146(6):607-612, 1983. e-Pub 1983. PMID: 6346879.
. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 28(1):101-114, 1983. e-Pub 1983. PMID: 6409485.
. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res 43(3):1395-1401, 1983. e-Pub 1983. PMID: 6825108.
. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res 43(3):1389-1394, 1983. e-Pub 1983. PMID: 6337707.
. Enhanced arachidonic acid lipoxygenation by K562 cells stimulated with 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 43(1):197-201, 1983. e-Pub 1983. PMID: 6401164.
. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 79(1):98-104, 1983. e-Pub 1983. PMID: 6336888.
Sang DN, Duncan J, Rodrick M, Steele G, Schepens CL, Bast RC. Circulating immune complex levels in peripheral uveitis: Discriminant analysis. Proceedings of the XXIV International Congress of Ophthalmology:453-459, 1983. e-Pub 1983.
. In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. Haematol Blood Transfus 28:117-123, 1983. e-Pub 1983. PMID: 6345287.
. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 2(3):275-285, 1983. e-Pub 1983. PMID: 6196309.
. Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. Int J Immunopharmacol 5(4):307-314, 1983. e-Pub 1983. PMID: 6629591.

1977�C1982

. Bystander suppression of tumor growth: evidence that specific targets and bystanders are damaged by injury to a common microvasculature. J Immunol 129(2):890-899, 1982. e-Pub 1982. PMID: 6282973.
. Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement. Lancet 2(8289):60-3, 1982. e-Pub 1982. PMID: 6177990.
. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68(5):1331-1337, 1981. e-Pub 1981. PMID: 7028788.
. Elimination of leukemic cells from rat bone marrow using antibody and complement. Cancer Res 41(9 Pt 1):3331-3335, 1981. e-Pub 1981. PMID: 6942913.
. Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood 58(2):333-336, 1981. e-Pub 1981. PMID: 6941821.
. Aryl hydrocarbon (benzo[a]pyrene) hydroxylase in guinea pig lymphoid tissue. J Natl Cancer Inst 67(2):359-364, 1981. e-Pub 1981. PMID: 6943374.
. HL-A antigen frequency distribution in patients with gestational choriocarcinoma and their husbands. Placenta Suppl 3:263-267, 1981. e-Pub 1981. PMID: 6963960.
. Immunoprophylaxis of syngeneic methycholanthrene-induced murine sarcomas with Bacillus Calmette-Guerin and tumor cells. Cancer Res 40(4):1036-1042, 1980. e-Pub 1980. PMID: 7357533.
. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 68(3):370-376, 1980. e-Pub 1980. PMID: 6965819.
. Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. J Natl Cancer Inst 64(2):365-372, 1980. e-Pub 1980. PMID: 6986493.
. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity. J Immunol 123(5):1945-1951, 1979. e-Pub 1979. PMID: 489967.
. Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins. Cancer Res 37(11):3904-3911, 1977. e-Pub 1977. PMID: 561657.

�鶹ӳ��